Zhou Lei, Lu Xia, Feng Zhen-gen, Shen Xiao-xia, Wu Jun-qing
Jinhua Municipal Hospital of Chinese Medicine, Jinhua 321017, China.
Zhen Ci Yan Jiu. 2011 Feb;36(1):52-6.
To evaluate the clinical therapeutic effect of acupoint-catgut-embedment therapy in the treatment of mammary gland hyperplasia (MGH).
Eighty MGH patients were equally randomized into acupoint-catgut-embedment (ACE) group and medication (Rupixiao, a herbal patent drug for relieving MGH) group according to odd-numbered days or even-numbered days of visiting. Subcutaneous catgut-embedment was performed in Wuyi (ST 15), Rugen (ST 18), Tanzhong (CV 17), Xuehai (SP 10), Zusanli (ST 36) and Yanglingquan (GB 34), once every 15 days for 3 months. Patients of the medication group were treated by oral administration of Rupixiao (3 tablets, 3 times per day, 3 months altogether). The degree of breast pain and the size of the hyperplastic lump were observed before and after the treatment. Serum estrodiol, progesterone and prolactin contents on day 1 to day 3 of menstruation were detected by using an automation chemiluminescence immune analysator.
After the treatment, of the two 40 MGH patients in the ACE and medication groups, 16 (40. 0%) and 5 (12. 5%) were cured basically, 8 (20. 0%) and 8 were improved markedly in their symptoms and signs, 16 (40. 0%) and 22 (55. 0%) were effective, and 0 and 5 (12. 5%) failed in the treatment, with the effective rates being 100% and 87.5%, respectively. The therapeutic effect of the ACE group was significantly better than that of the medication group (P<0. 05). In comparison with the pretreatment, the pain grades and the size of the hyperplastic lump in both ACE and medication groups decreased significantly after immediate termination of the treatment and 6 months after the treatment (P<0.01), and the therapeutic effects of the ACE group were significantly superior to those of the medication group in reducing pain grade and hyperplastic lump size (P<0. 01). After the treatment, serum estrodiol and progesterone contents were decreased evidently in both ACE and medication groups (P<0. 01, P<0. 05). Type-B ultrasonic examination showed that of the two 40 MGH patients in the ACE and medication groups, 16 and 5 cases turned to normal in their mammary glands, and the cure rate of the ACE group was evidently higher than that of the medication group (P<0. 01).
Acupoint-catgut-embedment is effective in relieving MGH, and its therapeutic effect is apparently superior to that of medication (oral administration of Rupixiao).
评价穴位埋线疗法治疗乳腺增生症(MGH)的临床疗效。
80例MGH患者按就诊日期奇偶数分为穴位埋线(ACE)组和药物(乳癖消,一种治疗MGH的中药专利药)组。于屋翳(ST15)、乳根(ST18)、膻中(CV17)、血海(SP10)、足三里(ST36)及阳陵泉(GB34)行皮下埋线,每15天1次,共3个月。药物组患者口服乳癖消治疗(3片,每日3次,共3个月)。观察治疗前后乳房疼痛程度及增生肿块大小。采用全自动化学发光免疫分析仪检测月经第1~3天血清雌二醇、孕酮及催乳素含量。
治疗后,ACE组和药物组40例MGH患者中,基本治愈分别为16例(40.0%)和5例(12.5%),症状体征明显改善分别为8例(20.0%)和8例,有效分别为16例(40.0%)和22例(55.0%),无效分别为0例和5例(12.5%),有效率分别为100%和87.5%。ACE组疗效明显优于药物组(P<0.05)。与治疗前比较,ACE组和药物组治疗结束时及治疗后6个月乳房疼痛分级及增生肿块大小均明显降低(P<0.01),且ACE组在减轻疼痛分级及增生肿块大小方面疗效明显优于药物组(P<0.01)。治疗后,ACE组和药物组血清雌二醇及孕酮含量均明显降低(P<0.01,P<0.05)。B超检查显示,ACE组和药物组40例MGH患者中,乳腺恢复正常分别为16例和5例,ACE组治愈率明显高于药物组(P<0.01)。
穴位埋线治疗MGH有效,其疗效明显优于药物(口服乳癖消)治疗。